Major block deals in Meesho and Lenskart are hitting the market today, alongside fresh US FDA inspection reports for several pharmaceutical companies. Investors are watching for potential price swings due to increased share supply and monitoring how pharma firms address these regulatory observations.
Investors have a busy start to the trading day on August 24, 2026, as several high-profile block deals and regulatory updates take center stage. The market is weighing the impact of large stake sales in the e-commerce sector while assessing the operational status of major pharmaceutical manufacturers following recent US FDA inspections.
Block Deals in E-commerce
Significant supply pressure is expected in the e-commerce space today. Y Combinator is offloading a 1.05 percent stake in Meesho through a block deal valued at approximately Rs 957.5 crore, with a floor price set at Rs 197.5 per share. Similarly, investment firm SoftBank Vision Fund II is preparing to sell up to 2.6 percent of its holding in the online eyewear retailer Lenskart. This transaction is estimated at roughly $300 million, with a floor price of Rs 635 per share.
For investors, these deals typically represent institutional exits rather than operational failures. When large private equity or venture capital investors sell stakes, it often creates a temporary supply of shares in the secondary market, which can influence short-term price movement. Investors often track whether new buyers absorb this supply or if it creates a temporary price dip.
Pharma Compliance and FDA Inspections
Several pharmaceutical companies are currently navigating regulatory checks after receiving Form 483 observations from the US Food and Drug Administration (US FDA). Caplin Point Laboratories reported 10 procedural observations at its manufacturing site, while Natco Pharma received four observations following an inspection of its Visakhapatnam facility. Additionally, Choksi Laboratories received four observations regarding its central laboratory in Indore. Aurobindo Pharma’s subsidiary, AuroPeptides, also received one observation.
It is important for investors to distinguish between types of FDA feedback. A Form 483 is a notification of findings that the regulator believes may constitute a violation of the Food Drug and Cosmetic Act; it is a request for the company to explain how they will fix the issues. In their initial responses, these companies have clarified that the observations are procedural and do not pertain to critical issues like data integrity. While these events are standard for pharma companies with export-heavy models, they serve as a reminder that procedural compliance is essential to avoid more severe actions, such as warning letters or import alerts, which could disrupt revenue in the lucrative US market.
Banking and Energy Updates
In other developments, Bank of Baroda successfully issued $400 million in senior unsecured notes through its IFSC Banking Unit in GIFT City, carrying an all-in yield of 5.389 percent. This reflects continued access to international capital markets for Indian lenders. Meanwhile, NTPC Renewable Energy, a subsidiary of NTPC Green Energy, has secured 500 MW of capacity in a recent auction at a tariff of Rs 6.00 per kWh for assured peak supply, highlighting the ongoing expansion in the renewable energy sector.
As the week progresses, investors will likely monitor how the stock prices of the involved pharma companies recover or react once they submit their formal compliance plans to the FDA. For the block deals, the key factor will be the depth of demand from institutional buyers to absorb the shares being sold.